Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of 2 Dose Regimens of Telaprevir [VX-950] in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C

Next Previous
X
Search
Trial Profile

A Phase 3 Study of 2 Dose Regimens of Telaprevir [VX-950] in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Vertex Pharmaceuticals

    • Most Recent Events

    • 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
    • 20 May 2015 Results of pooled data from ADVANCE, QUEST 1 and 2 trials comparing efficacy of simeprevir and telaprevir presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 30 Jun 2012 Additional location (United Kingdom) added as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top